Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Drug Development Pipeline Review, 2018 - Product Thumbnail Image

Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Drug Development Pipeline Review, 2018

  • Report
  • 159 Pages
From
Gastroparesis Global Clinical Trials Review, H2, 2017 - Product Thumbnail Image

Gastroparesis Global Clinical Trials Review, H2, 2017

  • Clinical Trials
  • 102 Pages
From
Gastrointestinal Bleeding (Gastrointestinal Hemorrhage) Global Clinical Trials Review, H2, 2017 - Product Thumbnail Image

Gastrointestinal Bleeding (Gastrointestinal Hemorrhage) Global Clinical Trials Review, H2, 2017

  • Clinical Trials
  • 117 Pages
From
Diabetic Gastroparesis Global Clinical Trials Review, H2, 2017 - Product Thumbnail Image

Diabetic Gastroparesis Global Clinical Trials Review, H2, 2017

  • Clinical Trials
  • 65 Pages
From
Hepatic Encephalopathy Global Clinical Trials Review, H2, 2017 - Product Thumbnail Image

Hepatic Encephalopathy Global Clinical Trials Review, H2, 2017

  • Clinical Trials
  • 107 Pages
From
Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2018 - Product Thumbnail Image

Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2018

  • Report
  • 101 Pages
From
Liver Cirrhosis - Pipeline Review, H1 2018 - Product Thumbnail Image

Liver Cirrhosis - Pipeline Review, H1 2018

  • Report
  • 88 Pages
From
Liver Failure (Hepatic Insufficiency) - Pipeline Review, H2 2017 - Product Thumbnail Image

Liver Failure (Hepatic Insufficiency) - Pipeline Review, H2 2017

  • Report
  • 80 Pages
From
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2018 - Product Thumbnail Image

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2018

  • Report
  • 237 Pages
From
Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H1 2018 - Product Thumbnail Image

Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H1 2018

  • Report
  • 512 Pages
From
Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2017 - Product Thumbnail Image

Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2017

  • Report
  • 446 Pages
From
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2017 - Product Thumbnail Image

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2017

  • Report
  • 202 Pages
From
Liver Failure - Pipeline Insight, 2018 - Product Thumbnail Image

Liver Failure - Pipeline Insight, 2018

  • Drug Pipelines
  • 50 Pages
From
Liver Cirrhosis Global Clinical Trials Review, H2, 2017 - Product Thumbnail Image

Liver Cirrhosis Global Clinical Trials Review, H2, 2017

  • Clinical Trials
  • 300 Pages
From
Hepatic Injury Global Clinical Trials Review, H2, 2017 - Product Thumbnail Image

Hepatic Injury Global Clinical Trials Review, H2, 2017

  • Clinical Trials
  • 56 Pages
From
Hyperammonemia Global Clinical Trials Review, H2, 2017 - Product Thumbnail Image

Hyperammonemia Global Clinical Trials Review, H2, 2017

  • Clinical Trials
  • 43 Pages
From
Irritable Bowel Syndrome (IBS) Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Irritable Bowel Syndrome (IBS) Therapeutics - Global Strategic Business Report

  • Report
  • 433 Pages
From
Hepatic Encephalopathy - Pipeline Review, H1 2018 - Product Thumbnail Image

Hepatic Encephalopathy - Pipeline Review, H1 2018

  • Report
  • 64 Pages
From
Hepatic Encephalopathy - Pipeline Review, H2 2017 - Product Thumbnail Image

Hepatic Encephalopathy - Pipeline Review, H2 2017

  • Report
  • 60 Pages
From
Hepatic Encephalopathy - Pipeline Insight, 2018 - Product Thumbnail Image

Hepatic Encephalopathy - Pipeline Insight, 2018

  • Drug Pipelines
  • 50 Pages
From
Loading Indicator
adroll